Stock Movers 3M Profit Outlook Light; Netflix Amends Warner Bros. Deal; GSK to Buy Rapt Therapeutics
Jan 20, 2026
3M's profit outlook disappoints with adjusted earnings falling below analyst expectations, highlighting a slowdown in growth momentum. Netflix shakes things up with an amended all-cash deal for Warner Bros. Discovery, igniting speculation over potential bidding wars with Paramount. Meanwhile, GSK makes headlines by agreeing to acquire Rapt Therapeutics for $2.2 billion, focusing on treatments for inflammatory diseases and food allergies. This strategic move represents a significant premium and signals GSK's shift towards immunology and oncology.
AI Snips
Chapters
Transcript
Episode notes
3M Momentum Is Slowing
- 3M's operational improvements lifted last year's results but momentum is cooling heading into 2026.
- Slower organic growth and a cautious EPS outlook caused shares to drop despite recent turnaround efforts.
3M's Diverse Product Examples
- Lisa Mateo illustrates 3M's product breadth from Post-it notes to AI-focused electrical materials and nuclear components.
- She cites data center and reactor-related businesses as recent drivers of 3M's performance.
Netflix Switches To All-Cash Offer
- Netflix amended its offer to pay Warner Bros. Discovery all cash to speed up the sale process.
- The company expects shareholders to vote by April but the outcome could still trigger counterbids from Paramount Skydance.